Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 129

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 129
---
 its requirements,
NewGenIvf may seek to issue debt or equity securities or obtain additional credit facilities. Financing may be unavailable in the amounts
NewGenIvf needs or on terms acceptable to it, if at all. Issuance of additional equity securities, including convertible debt securities,
would dilute NewGenIvf’s earnings per share. The incurrence of debt would divert cash for working capital and capital expenditures
to service debt obligations and could result in operating and financial covenants that restrict NewGenIvf’s operations and its
ability to pay dividends to its shareholders. If NewGenIvf is unable to obtain additional equity or debt financing as required, its business
operations and prospects may suffer. Please see “Risk Factors — Risks Relating to NewGenIvf’s Business and Industry — NewGenIvf requires a significant amount of capital to fund its operations and growth. If NewGenIvf cannot obtain sufficient capital on acceptable terms, its business, financial condition, and prospects may be materially and adversely affected.”

The following table presents
NewGenIvf’s selected consolidated cash flow data for the periods indicated.

|                                                                     |     | For Six Months ended 
             June 30, |            |   |     |      |            |   |
|                                                                     |     |                 2025 |            |   |     | 2024 |            |   |
|                                                                     |     |                  US$ |            |   |     |      |            |   |
| Net cash used in operating activities                               |     |                      |   (895,065 | ) |     |      |  4,209,695 |   |
| Net cash used in investing activities                               |     |                      | (7,542,785 | ) |     |      |    (11,449 | ) |
| Net cash provided by financing activities                           |     |                      |  9,963,297 |   |     |      | (4,352,923 | ) |
| Net increase in cash and cash equivalents                           |     |                      |  1,525,447 |   |     |      |   (154,677 | ) |
| Effect of foreign currency translation on cash and cash equivalents |     |                      |   (374,711 | ) |     |      |    284,681 |   |
| Cash and cash equivalents, beginning of the period                  |     |                      |    457,740 |   |     |      |     54,104